

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



和 鉑 醫 藥 控 股 有 限 公 司

HBM Holdings Limited

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 02142)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE 2025 ANNUAL REPORT AND THE 2026 INTERIM REPORT

Reference is made to the annual report of HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) for the year ended 31 December 2025 published on 28 April 2026 (the “**2025 Annual Report**”) and the interim report of the Company for the six months ended 30 June 2026 published on 10 September 2026 (the “**2026 Interim Report**”). Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the 2025 Annual Report and the 2026 Interim Report.

The board of directors of the Company (the “**Board**”) would like to provide supplemental information on Batoclimab (HBM9161), a Core Product of the Company under Chapter 18A of the Listing Rules. In July 2024, the NMPA accepted the BLA of Batoclimab (HBM9161) for the treatment of gMG. Batoclimab (HBM9161) is expected to receive drug marketing authorization from the NMPA in the second half of 2026, subject to the outcome of regulatory review, and, if the development is successful, reach commercialization shortly thereafter. The commercialization in Greater China (including Hong Kong, Macau and Taiwan) will be conducted by NBP Pharma pursuant to the license agreement entered into by the Group and NBP Pharma on 10 October 2022. Save as disclosed above, all other information in the 2025 Annual Report and the 2026 Interim Report remains unchanged.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 21 September 2026

As at the date of this announcement, the Board comprises Dr. Jingsong Wang, Mr. Youchen Chen and Dr. Ian Yi Liu as executive Directors; and Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.